1naresh2naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1d9652cb-4003-44a3-a4b4-75572c700ab1] => Array ( [runtime-id] => 1d9652cb-4003-44a3-a4b4-75572c700ab1 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [16eb4c33-c122-4349-9d4a-dc03dd6f1525] => Array ( [runtime-id] => 16eb4c33-c122-4349-9d4a-dc03dd6f1525 [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;37f3cead3e7a02124df5156c871a5aba3dca9f5a ) ) ) 1naresh2nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) [1d9652cb-4003-44a3-a4b4-75572c700ab1] => Array ( [runtime-id] => 1d9652cb-4003-44a3-a4b4-75572c700ab1 [type] => toll-free-key [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [16eb4c33-c122-4349-9d4a-dc03dd6f1525] => Array ( [runtime-id] => 16eb4c33-c122-4349-9d4a-dc03dd6f1525 [type] => toll-free-key ) ) [credentials] => Array ( [method] => toll-free-key [value] => tf_ipsecsha;37f3cead3e7a02124df5156c871a5aba3dca9f5a ) ) )Table 2:Intraindividual comparison of model-free and pharmacokinetic parameters between gadobutrol and gadoterate meglumine dynamic contrast-enhanced MR imaginga
DCE Parameter Gadobutrol Gadoterate Meglumine P Value Model-free method IAUC30 3.91 ± 2.38 4.27 ± 2.02 .517 IAUC100 21.50 ± 12.82 23.41 ± 11.28 .530 IAUC200 39.08 ± 23.30 42.53 ± 20.57 .533 IAUC300 56.68 ± 33.77 61.68 ± 29.88 .533 IAUC400 74.25 ± 44.24 80.79 ± 39.17 .534 IAUC500 91.84 ± 54.71 99.91 ± 48.46 .534 IAUC600 109.44 ± 65.19 119.06 ± 57.76 .534 IAUC700 127.04 ± 75.66 138.21 ± 67.07 .535 IAUC800 144.66 ± 86.13 157.37 ± 76.37 .535 IAUC900 166.69 ± 98.74 179.04 ± 83.13 .656 IAUC1000 184.76 ± 109.43 198.43 ± 92.13 .656 IAUC1100 202.85 ± 120.13 217.84 ± 101.13 .657 Pharmacokinetic method Ktrans (min–1) 0.016 ± 0.009 0.017 ± 0.008 .592 Kep (min–1) 0.127 ± 0.042 0.132 ± 0.041 .594 Ve (%) 17.797 ± 10.057 17.271 ± 7.436 .813 Vp 1.168 ± 0.674 1.263 ± 0.600 .559 Wash-in rate 0.825 ± 0.644 0.289 ± 0.634 .013 Washout rate 0.0010 ± 0.0008 0.0021 ± 0.0025 .024
↵a Data area means. P values are from paired tests when the variables satisfied normality according to the Shapiro-Wilk test or from Wilcoxon-signed rank tests otherwise.